It researches drugs based on messenger RNA (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases. In 2020, the company started developing the BNT162b2 vaccine against SARS-CoV-2 with Pfizer and Fosun. In late 2020 BioNTech successfully developed, together with Pfizer, the RNA vaccine called BNT162b2 against COVID-19. The company said, it's vaccine efficacy was 95%. On 2 December 2020, the United Kingdom government gave permission to use BNT162b2 vaccinations in the country. Later in December 2020 USA, Canada and the EU also gave permission to use the BioNTech vaccine.
References[change | change source]
- Form F-1 BioNTech SE (Report). U.S. Securities and Exchange Commission. 9 September 2019. Retrieved 13 October 2019.
- Lovelace Jr., Berkeley (27 July 2020). "Pfizer and BioNTech began late-stage human trial for coronavirus vaccine Monday". CNBC. Retrieved 2 August 2020.
- "BioNTech in China alliance with Fosun over coronavirus vaccine candidate". Reuters. Frankfurt. 15 March 2020. Retrieved 2 August 2020.
- Burger, Ludwig (22 April 2020). "Germany approves trials of COVID-19 vaccine candidate". Reuters. Berlin. Retrieved 2 August 2020.
- releases, 8:30am to 5pm For real-time updates including the latest press; Statements, News; https://www.twitter.com/mhragovuk, see our Twitter channel at. "UK medicines regulator gives approval for first UK COVID-19 vaccine". GOV.UK. Retrieved 2021-01-25.
- Commissioner, Office of the (2021-01-07). "Pfizer-BioNTech COVID-19 Vaccine Frequently Asked Questions". FDA.
- Canada, Health (2020-12-09). "Pfizer-BioNTech COVID-19 vaccine: What you should know". aem. Retrieved 2021-01-25.
- "Commission approves BioNTech/Pfizer vaccine". POLITICO. 2020-12-21. Retrieved 2021-01-25.